References

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

10.1016/j.jacc.2012.11.018 · 2013 · External reference

Door-to-balloon time and mortality among patients undergoing primary PCI

10.1056/nejmoa1208200 · 2013 · External reference

Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward

10.1161/circoutcomes.112.966150 · 2012 · External reference

Long-term trends in the incidence of heart failure after myocardial infarction

10.1161/circulationaha.108.784215 · 2008 · External reference

Time to take reperfusion injury seriously

10.1056/nejme0803746 · 2008 · External reference

Myocardial reperfusion injury

10.1056/nejmra071667 · 2007 · External reference

Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction

10.1161/01.cir.101.18.2154 · 2000 · External reference

Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo

10.1007/s00395-005-0537-4 · 2005 · External reference

Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure

10.1152/ajpheart.00054.2011 · 2011 · External reference

Intracoronary injection of adenosine before reperfusion in patients with ST-segment elevation myocardial infarction: a randomized controlled clinical trial

10.1016/j.ijcard.2014.09.203 · 2014 · External reference

A single dose of erythropoietin in ST-elevation myocardial infarction

10.1093/eurheartj/ehq304 · 2010 · External reference

Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial

10.1001/jama.2014.3315 · 2014 · External reference

Myocardial reperfusion: a double-edged sword?

10.1172/jci112160 · 1985 · External reference

Reperfusion conditions: importance of ensuring gentle versus sudden reperfusion during relief of coronary occlusion

10.1016/s0022-5223(19)36512-2 · 1985 · External reference

Evolving therapies for myocardial ischemia/reperfusion injury

10.1016/j.jacc.2015.02.032 · 2015 · External reference

Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion

10.1042/bj3070093 · 1995 · External reference

The Ca2+-induced membrane transition in mitochondria. I. The protective mechanisms

10.1016/0003-9861(79)90371-0 · 1979 · External reference

Cardioprotection and myocardial reperfusion: pitfalls to clinical application

10.1161/circresaha.113.300765 · 2013 · External reference

The mitochondrial permeability transition pore: molecular nature and role as a target in cardioprotection

10.1016/j.yjmcc.2014.09.023 · 2015 · External reference

Myocardial ischemia-reperfusion injury: a neglected therapeutic target

10.1172/jci62874 · 2013 · External reference

Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium

10.1161/01.cir.74.5.1124 · 1986 · External reference

Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?

10.1016/s0008-6363(02)00455-8 · 2002 · External reference

Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart

10.1113/jphysiol.2003.034231 · 2003 · External reference

Ischemic preconditioning protects against infarction in rat heart

1992 · External reference

Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction

10.1161/01.cir.88.3.1264 · 1993 · External reference

Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia

10.1161/01.res.72.6.1293 · 1993 · External reference

The time limit of effective ischemic preconditioning in dogs

1990 · External reference

Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning

2003 · External reference

Molecular basis of cardioprotection signal transduction in ischemic pre-, post-, and remote conditioning

10.1161/circresaha.116.305348 · 2015 · External reference

Reduction of myocardial infarct size with ischemic “conditioning”: physiologic and technical considerations

10.1213/ane.0b013e318294fc63 · 2013 · External reference

Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion

10.1016/j.cardiores.2004.01.006 · 2004 · External reference

Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction: the randomized LIPSIA CONDITIONING trial

10.1093/eurheartj/ehv463 · 2015 · External reference

History of the discovery of cyclosporin and of its early pharmacological development

2002 · External reference

From Norway to Novartis: cyclosporin from tolypocladium inflatum in an open access bioprospecting regime

10.1023/a:1008990919682 · 2000 · External reference

Unresolved reference

2015 · External reference

Inhibition by cyclosporin A of a Ca2+-dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress

1988 · External reference

Protection by cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts

10.1006/jmcc.1993.1162 · 1993 · External reference

Inhibition of anoxia-induced injury in heart myocytes by cyclosporin A

10.1016/0022-2828(91)90181-k · 1991 · External reference

Comparative analysis of different cyclosporine A doses on protection after myocardial ischemia/reperfusion injury in rat

10.1016/s1995-7645(14)60011-0 · 2014 · External reference

Inhibition of mitochondrial permeability transition improves functional recovery and reduces mortality following acute myocardial infarction in mice

10.1152/ajpheart.01378.2006 · 2007 · External reference

Transient metabolic alkalosis during early reperfusion abolishes helium preconditioning against myocardial infarction: restoration of cardioprotection by cyclosporin A in rabbits

10.1213/ane.0b013e318193e934 · 2009 · External reference

Cyclosporine A at reperfusion fails to reduce infarct size in the in vivo rat heart

10.1007/s00395-013-0379-4 · 2013 · External reference

Cyclosporine A reduces microvascular obstruction and preserves left ventricular function deterioration following myocardial ischemia and reperfusion

10.1007/s00395-015-0475-8 · 2015 · External reference

2.5 mg/kg, does not reduce myocardial infarct size in a porcine model of ischemia and reperfusion

10.1177/1074248411407636 · 2012 · External reference

Cyclosporine does not reduce myocardial infarct size in a porcine ischemia-reperfusion model

10.1177/1074248410362074 · 2010 · External reference

Postconditioning does note reduce myocardial infarct size in an in vivo regional ischemia rodent model

10.1177/1074248407300897 · 2007 · External reference

Effect of cyclosporine on reperfusion injury in acute myocardial infarction

10.1056/nejmoa071142 · 2008 · External reference

The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction

10.1111/1755-5922.12010 · 2013 · External reference

Cyclosporine protects the heart during aortic valve surgery

10.1097/aln.0000000000000331 · 2014 · External reference

The effect of cyclosporine-A on peri-operative myocardial injury in adult patients undergoing coronary artery bypass graft surgery: a randomised controlled clinical trial

10.1136/heartjnl-2013-304845 · 2014 · External reference

Cyclosporine A in reperfused myocardial infarction

10.1016/j.jacc.2015.10.081 · 2016 · External reference

Cyclosporine before PCI in patients with acute myocardial infarction

10.1056/nejmoa1505489 · 2015 · External reference

Rationale and design of the Cyclosporine to ImpRove Clinical oUtcome in ST-Elevation Myocardial Infarction Patients (the CIRCUS trial)

10.1016/j.ahj.2015.02.020 · 2015 · External reference

TRO40303, a new cardioprotective compound, inhibits mitochondrial permeability transition

10.1124/jpet.110.167486 · 2010 · External reference

Translation of TRO40303 from myocardial infarction models to demonstration of safety and tolerance in a randomized phase I trial

10.1186/1479-5876-12-38 · 2014 · External reference

Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results

10.1093/eurheartj/ehu331 · 2014 · External reference

Potent mitochondria-targeted peptides reduce myocardial infarction in rats

10.1097/01.mca.0000236285.71683.b6 · 2007 · External reference

Mitochondrial permeability transition in the diabetic heart: contributions of thiol redox state and mitochondrial calcium to augmented reperfusion injury

10.1016/j.yjmcc.2012.02.009 · 2012 · External reference

Reduction of ischemia/reperfusion injury with bendavia, a mitochondria-targeting cytoprotective peptide

10.1161/jaha.112.001644 · 2012 · External reference

Reduction of early reperfusion injury with the mitochondria-targeting peptide bendavia

10.1177/1074248413508003 · 2014 · External reference

EMBRACE STEMI study : a phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention

10.1093/eurheartj/ehv597 · 2016 · External reference

All is not well in the world of translational research

10.1016/j.jacc.2007.04.067 · 2007 · External reference

Pilot trials in clinical research: of what value are they?

10.1161/circulationaha.109.861625 · 2009 · External reference